MedTrace Logo

Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

NCT01183663 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-06-03

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer. The safety of the drug combinations will also be studied.

Conditions

Interventions

DRUG

Lenalidomide

Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.

DRUG

Bevacizumab

Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.

DRUG

Sorafenib

Starting dose: 200 mg by mouth daily for 28 a day cycle.

DRUG

Temsirolimus

Starting dose: 15 mg by vein every week for a 28 day cycle.

DRUG

Lenalidomide

Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.

DRUG

Oxaliplatin

Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.

DRUG

Leucovorin

400 mg/m2 by vein on day 1 of a 21 day cycle.

DRUG

5-fluorouracil

400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.

Sponsors & Collaborators

  • Celgene

    collaborator INDUSTRY

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Apostolia M. Tsimberidou, MD, PhD · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01183663 on ClinicalTrials.gov